Loading...
•
Sep 30, 2022
Ocular Therapeutix Q3 2022 Earnings Report
Ocular Therapeutix reported financial results for the third quarter of 2022 and provided updates on its ophthalmology pipeline.
Key Takeaways
Ocular Therapeutix reported net revenue of $12.0 million for Q3 2022, a 2% decrease compared to the same period in 2021. DEXTENZA net product revenue was $11.9 million, flat compared to Q3 2021. The company's net loss for the quarter was $(24.2) million, or $(0.31) per share.
Presented positive interim data from the U.S.-based Phase 1 clinical trial of OTX-TKI for the treatment of wet AMD at the AAO 2022 Annual Meeting.
Initiation of OTX-TKI Phase 1 Clinical Trial for the treatment of Diabetic Retinopathy planned for Q1 of 2023.
Phase 2/3 Clinical Trial for the treatment of Wet AMD planned for Q3 of 2023.
DEXTENZA® recorded quarterly net product revenue of $11.9 Million.
Ocular Therapeutix
Ocular Therapeutix
Ocular Therapeutix Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.com Forward Guidance
Revised DEXTENZA Annual Net Product Revenue Guidance for 2022 to be between $48 to $52 million, Representing Annual Growth of Approximately 10% to 20%.